Generic Rykindo Availability
Last updated on Aug 7, 2024.
Rykindo is a brand name of risperidone, approved by the FDA in the following formulation(s):
RYKINDO (risperidone - for suspension, extended release;intramuscular)
-
Manufacturer: SHANDONG LUYE
Approval date: January 13, 2023
Strength(s): 12.5MG [RLD], 25MG [RLD], 37.5MG [RLD], 50MG [RLD]
Has a generic version of Rykindo been approved?
No. There is currently no therapeutically equivalent version of Rykindo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rykindo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Risperidone sustained release microsphere composition
Patent 10,098,882
Issued: October 16, 2018
Inventor(s): Sun Kaoxiang & Liang Rongcai & Wang Qilin & Wang Wenyan & Liu Wanhui & Li YouxinA risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Patent expiration dates:
- April 10, 2032✓✓
- April 10, 2032
-
Risperidone sustained release microsphere composition
Patent 10,406,161
Issued: September 10, 2019
Inventor(s): Sun Kaoxiang & Liang Rongcai & Wang Qilin & Wang Wenyan & Liu Wanhui & Li YouxinA risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Patent expiration dates:
- April 10, 2032✓✓
- April 10, 2032
-
Patent 11,110,094
Patent expiration dates:
- April 10, 2032✓
- April 10, 2032
-
Risperidone sustained release microsphere composition
Patent 9,446,135
Issued: September 20, 2016
Inventor(s): Sun Kaoxiang & Liang Rongcai & Wang Qilin & Wang Wenyan & Liu Wanhui & Li Youxin
Assignee(s): Shandong Luye Pharmaceutical Co., Ltd.A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Patent expiration dates:
- April 10, 2032✓✓
- April 10, 2032
-
Risperidone sustained release microsphere composition
Patent 9,532,991
Issued: January 3, 2017
Inventor(s): Sun Kaoxiang & Liang Rongcai & Wang Qilin & Wang Wenyan & Liu Wanhui & Li YouxinA risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
Patent expiration dates:
- April 10, 2032✓✓
- April 10, 2032
More about Rykindo (risperidone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
Patient resources
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris, ... +2 more
Professional resources
Other brands
Risperdal, Uzedy, Risperdal Consta, Perseris
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.